Q-omics provides the consensus-scored ZNF177 profile across patient tissues and cancer cell-line models. ZNF177 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, ZNF177 is differentially expressed in 5, with the highest sampling consensus in KICH. Additionally, ZNF177 RNA expression shows 16,944 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCEC, KICH, and THYM as cancer lineages where ZNF177 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF177 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF177 survival associations across molecular data types. ZNF177 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF177 RNA expression–survival associations across cancer types. High ZNF177 expression shows unfavorable associations in ESCA and CHOL, but favorable associations in UCEC, LAML, ACC and GBM. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify UCEC as the clearest survival context for ZNF177 RNA expression.
This table summarizes ZNF177 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF177. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF177 shows lower tumor expression in PAAD and higher tumor expression in KICH, LUSC, PRAD and COAD. The KICH box plot shows higher ZNF177 RNA expression in tumor versus normal tissue (log2 FC = +0.046, t-test p = .007).
This table shows molecular features associated with ZNF177 in patient tissues and cancer cell lines. In patient samples, ZNF177 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF177 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
